CTMX: CytomX Therapeutics Inc. Stocks News on June 7, 2025

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CTMX

GlobeNewswire

9 days ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

CTMX

GlobeNewswire

19 days ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

CTMX

MT Newswires

23 days ago

HC Wainwright Upgrades CytomX Therapeutics to Buy From Neutral, Price Target is $5

CTMX

Thomson Reuters StreetEvents

25 days ago

Q1 2025 CytomX Therapeutics Inc Earnings Call

CTMX

MT Newswires

a month ago

CytomX Shares Jump After Q1 Beat, 'Positive' Interim Trial Data

CTMX

MT Newswires

a month ago

Wedbush Adjusts CytomX Therapeutics Price Target to $6 From $5, Maintains Outperform Rating

CTMX

MT Newswires

a month ago

Top Premarket Gainers

CTMX

Zacks

a month ago

CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

CTMX

GlobeNewswire

a month ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

CTMX

Associated Press Finance

a month ago

CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

CTMX

GlobeNewswire

a month ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

CTMX

GuruFocus.com

a month ago

CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For

Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?

CTMX

Zacks

a month ago

Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

CTMX

GlobeNewswire

a month ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CTMX

GlobeNewswire

a month ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

CTMX

Zacks

a month ago

CytomX Gears Up to Report Q1 Earnings: Here's What to Expect

VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

CTMX

Zacks

2 months ago

VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

CTMX

Zacks

2 months ago

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

CTMX

Zacks

2 months ago

BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study

FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

CTMX

Zacks

2 months ago

FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda

GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

CTMX

Zacks

2 months ago

GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

CTMX

Zacks

2 months ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)

CTMX

Zacks

2 months ago

FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

CTMX

Zacks

3 months ago

Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

CTMX

Zacks

3 months ago

Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

CTMX

Zacks

3 months ago

Allogene's Q4 Loss Narrower Than Expected, Revenues Nil

CTMX

Zacks

3 months ago

CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations

CTMX

Simply Wall St.

3 months ago

CytomX Therapeutics Full Year 2024 Earnings: Beats Expectations

CTMX

Insider Monkey

3 months ago

CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now

CTMX

Thomson Reuters StreetEvents

3 months ago

Q4 2024 CytomX Therapeutics Inc Earnings Call

CTMX

GuruFocus.com

3 months ago

CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

CTMX

Zacks

3 months ago

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CTMX

GlobeNewswire

3 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CTMX

GlobeNewswire

3 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CTMX

GuruFocus.com

3 months ago

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result

CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?

CTMX

Zacks

3 months ago

CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

CTMX

GlobeNewswire

3 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

CTMX

Simply Wall St.

4 months ago

Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer

CTMX

Zacks

5 months ago

AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

CTMX

Zacks

5 months ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CTMX

GlobeNewswire

5 months ago

CytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CTMX

Zacks

5 months ago

All You Need to Know About CytomX Therapeutics (CTMX) Rating Upgrade to Strong Buy

CTMX

MT Newswires

5 months ago

Wedbush Adjusts CytomX Therapeutics' PT to $5 From $8, Keeps Outperform Rating

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

CTMX

GlobeNewswire

5 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

CTMX

Zacks

5 months ago

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

CTMX

Zacks

5 months ago

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CTMX

Zacks

5 months ago

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

CTMX

Zacks

5 months ago

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

CTMX

Zacks

5 months ago

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

CTMX

Zacks

5 months ago

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

CTMX

Zacks

5 months ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

CTMX

Zacks

6 months ago

CytomX Therapeutics (CTMX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

CTMX

Zacks

6 months ago

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Grifols Stock Declines After Brookfield Drops Buyout Offer

CTMX

Zacks

6 months ago

Grifols Stock Declines After Brookfield Drops Buyout Offer

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

CTMX

GlobeNewswire

6 months ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

CTMX

Zacks

6 months ago

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

CTMX

Zacks

7 months ago

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

CTMX

Zacks

7 months ago

Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%

CTMX

Zacks

7 months ago

Down -25.59% in 4 Weeks, Here's Why CytomX Therapeutics (CTMX) Looks Ripe for a Turnaround

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

CTMX

Zacks

7 months ago

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

CTMX

Simply Wall St.

7 months ago

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations

CTMX

Thomson Reuters StreetEvents

7 months ago

Q3 2024 CytomX Therapeutics Inc Earnings Call

CTMX

GuruFocus.com

7 months ago

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

CTMX

Zacks

7 months ago

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates

CTMX

Associated Press Finance

7 months ago

CytomX Therapeutics: Q3 Earnings Snapshot

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CTMX

GlobeNewswire

7 months ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

CTMX

GuruFocus.com

7 months ago

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CTMX

GlobeNewswire

7 months ago

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CTMX

GlobeNewswire

9 months ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CTMX

GlobeNewswire

9 months ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

CTMX

Simply Wall St.

10 months ago

CytomX Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

CTMX

Associated Press Finance

10 months ago

CytomX Therapeutics: Q2 Earnings Snapshot

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CTMX

GlobeNewswire

10 months ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

CTMX

GlobeNewswire

10 months ago

CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

CTMX

Insider Monkey

10 months ago

CytomX Therapeutics, Inc. (CTMX): The Best One-Dollar Stock to Buy Now?

CTMX

Simply Wall St.

a year ago

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is definitely on the radar of institutional investors who own 47% of the company

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

CTMX

Simply Wall St.

a year ago

Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

CytomX Therapeutics Announces New Employment Inducement Grants

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Announces New Employment Inducement Grants

CTMX

Insider Monkey

a year ago

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2024 Earnings Call Transcript

CTMX

MT Newswires

a year ago

BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating

CTMX

Thomson Reuters StreetEvents

a year ago

Q1 2024 CytomX Therapeutics Inc Earnings Call

CTMX

MT Newswires

a year ago

Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3

CTMX

GuruFocus.com

a year ago

CytomX Therapeutics Inc (CTMX) Q1 2024 Earnings Call Transcript Highlights: Strategic ...

CTMX

Associated Press Finance

a year ago

CytomX Therapeutics: Q1 Earnings Snapshot

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

CTMX

MT Newswires

a year ago

Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8

CTMX

Zacks

a year ago

CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

CTMX

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Situation

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CTMX

GlobeNewswire

a year ago

CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

CTMX

Simply Wall St.

a year ago

CytomX Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

CTMX

Insider Monkey

a year ago

Latest CytomX Therapeutics Inc. (CTMX) News on June 7, 2025

Share on Social Networks: